| 47th week of 2009 patent applcation highlights part 43 |
| Patent application number | Title | Published |
|---|
| 20090286795 | USE OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITORS FOR THE TREATMENT OF CANCER - The invention relates to a method for screening patients for tumor burden and the use of VEGF-R inhibitors alone or in combination with chemotherapy for the treatment of gastrointestinal, genitourinary, lymphoid and pulmonary (small cell and non-small cell) cancer patients and patients with cancers of neural crest origin having high serum or plasma LDH5 levels. | 2009-11-19 |
| 20090286796 | Compounds exhibiting type X sPLA2 inhibiting effect - A compound represented by the general formula: | 2009-11-19 |
| 20090286797 | Novel Quinoxaline Derivatives and Their Medical Use - This invention relates to novel quinoxaline derivatives having medical utility, to use of the quinoxaline derivatives of the invention for the manufacture of a medicament, to pharmaceutical compositions comprising the quinoxaline derivatives of the invention, and to methods of treating a disorder, disease or a condition of a subject, which disorder, disease or condition is responsive to positive modulation of AMPA receptor mediated synaptic responses. | 2009-11-19 |
| 20090286798 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES - Novel[1.2.4]triazolo[1,5-a]pyrazine and imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: | 2009-11-19 |
| 20090286799 | METHODS FOR THE TREATMENT OF BRAIN EDEMA - The present invention is based on the discoveries that PAN-811 (1) reduces infarct volume, suppresses brain edema and decreases mortality associated with ischemia; (2) blocks veratridine-induced swelling and neuronal cell death; (3) chelates free calcium and inhibits MMP-9 activity; and (4) blocks calcium-induced neuronal cell death and suppresses glutamate-induced calcium influx into neuronal cells. More particularly, the present invention relates to methods for treating, ameliorating or preventing vasogenic and/or cytotoxic brain edema, by administering to a subject in need thereof certain thiosemicarbazone compounds or pharmaceutically acceptable salts thereof. An example of such a thiosemicarbazone is 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (PAN-811). | 2009-11-19 |
| 20090286800 | Glucokinase Activators - Compounds are provided for use with glucokinase that comprise the formula: | 2009-11-19 |
| 20090286801 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS - The invention relates to compounds of the general formula (I): to the process for preparing them, and to the use thereof as a therapeutic agent. | 2009-11-19 |
| 20090286802 | High Dose Folic Acid Compositions for Vascular Dysfunction - The present invention relates to treatments for hypertension and more particularly, to the use of high dose folic acid in treating dysfunctional conditions associated with vascular function. High dose folic acid can increase vasodilator-stimulated myocardial blood flow and acutely lower arterial pressure independently of homocysteine lowering. | 2009-11-19 |
| 20090286803 | COMBINATION COMPRISING A) A PYRIMIDYLAMINOBENZAMIDE COMPOUND, AND B) A THR315LLE KINASE INHIBITOR - The invention provides a pharmaceutical combination comprising:
| 2009-11-19 |
| 20090286804 | METABOLITES OF 1-[6-(1-ETHYL-1-HYDROXY-PROPYL)-PYRIDIN-3-YL]-3-[2-(4-METHYL-PIPERAZIN-1-- YL)-BENZYL]-PYRROLIDIN-2-ONE AS SERATONIN RECEPTOR ANTAGONISTS - Metabolites of 1-[6-(1-ethyl-1-hydroxy-propyl)-pyridin-3-yl]-3-[2-(4-methyl-piperazin-1-yl)-benzyl]-pyrrolidin-2-one, and use of same. Metabolites of the present invention are as shown in Formula (II): (II) wherein R | 2009-11-19 |
| 20090286805 | Solubiliazation preparation - A solution-type preparation of lurasidone comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone) as an active ingredient and containing at least one substance selected from benzyl alcohol, N,N-dimethylacetamide, lactic acid and propylene glycol. | 2009-11-19 |
| 20090286806 | ISOXAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS - Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type or T-type calcium channel activity are disclosed. Specifically, a series of isoxazole containing compounds are disclosed of the general formula (1) where Z is N or CHNR | 2009-11-19 |
| 20090286807 | CYCLIC AMINE COMPOUND - The present invention provides an excellent antihypertensive medicament. The medicament of the present invention comprises a compound having the general formula (I) and the like: | 2009-11-19 |
| 20090286808 | Opsin Stabilizing Compounds and Methods of Use - The present invention provides compositions and methods useful in the treatment and/or prevention of ophthalmic conditions and diseases, such as retinitis pigmentosa, that are dependent upon or related to misfolded opsin proteins in vivo. In addition, screening assays for agents useful in such treatment methods are described. | 2009-11-19 |
| 20090286809 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound - The present invention relates to preventives or remedies for Alzheimer's disease, or to amyloid protein fibril-formation inhibitors, which include as an active ingredient a compound of general formula (I) below or a pharmacologically permitted salt thereof; and also to nitrogen-containing heteroaryl derivatives having specific substituents, or pharmacologically permitted salts thereof, which are valuable as preventives or remedies for Alzheimer's disease, or as amyloid protein fibril-formation inhibitors: | 2009-11-19 |
| 20090286810 | Pyrimidine Non-Classical Cannabinoid Compounds and Related Methods of Use - Disclosed are compounds of the formula I: | 2009-11-19 |
| 20090286811 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS - The present invention provides transient receptor potential vanilloid (TRPV) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. | 2009-11-19 |
| 20090286812 | GPR119 Receptor Agonists - Provided herein are compounds of the formula (I): | 2009-11-19 |
| 20090286813 | Thioxanthine Derivatives and Their Use as Inhibitors of MPO - There are disclosed novel compounds of Formula (I) wherein R | 2009-11-19 |
| 20090286814 | HCV PROTEASE INHIBITORS - This invention relates to macrocyclic compounds of formula (I) or (II) shown in the specification. These compounds can be used to treat hepatitis C virus infection. | 2009-11-19 |
| 20090286815 | Pyrimidine Classical Cannabinoid Compounds and Related Methods of Use - Disclosed are compounds of the formula I: | 2009-11-19 |
| 20090286816 | MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO - The present invention relates to 4-[5-Methoxy-6-(2-methyl-6-[1,2,4]triazol-1-yl-pyridin-3-ylamino)-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester, pharmaceutically acceptable salts, solvates and hydrates thereof that are modulators of glucose metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, | 2009-11-19 |
| 20090286817 | 4-Phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-Based Compounds and Methods of Their Use - Compounds of formula I are disclosed, as well as compositions comprising them and methods of their use to treat, prevent and/or manage diseases and disorders: | 2009-11-19 |
| 20090286818 | Pyridine Non-Classical Cannabinoid Compounds and Related Methods of Use | 2009-11-19 |
| 20090286819 | Process for Preparing the Calcium Salt of Rosuvastatin - An improved process for manufacture of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, which is useful for the production of a pharmaceutical useful in the treatment of, inter alia, hypercholesterolemia, hyperlipoproteinemia and atherosclerosis, is described. | 2009-11-19 |
| 20090286820 | (R)-PHENYL(HETEROCYCLE)METHANOL-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE - Multicyclic compounds, pharmaceutical compositions comprising them, and methods of their use are described. Compounds described include those of formula I: | 2009-11-19 |
| 20090286821 | INHIBITORS OF TYROSINE KINASES - The invention relates to compounds of formula | 2009-11-19 |
| 20090286822 | Treatment of psoriasis and of other skin disorders associated with inhibition of differentiation of epidermal cells - This invention concerns the use of cyclopamine, a naturally occurring steroidal alkaloid known for over thirty years, for the treatment of psoriasis and achievement of rapid clearance of the psoriatic skin lesions together with the reversion of the histopathological signs of disease to normalcy with no detectable side effects. The cyclopamine-induced clearance of psoriatic lesions from the skin of patients is associated with the causation of cellular differentiation in lesional epidermis and with the rapid disappearance of CD4(+) lymphocytes and other inflammatory cells from lesional skin. Therapeutic compositions comprising of cyclopamine and a corticosteroid and/or the pre-treatment of lesions with a corticosteroid provide significantly further increased therapeutic effectiveness over the use of cyclopamine alone or a corticosteroid alone. | 2009-11-19 |
| 20090286823 | CCR1 Inhibitors useful for the treatment of multiple myeloma and other disorders - The invention relates to the use of inhibitors of CCR1 for the treatment of cancers and osteolytic bone disorders. In some embodiments, the invention relates to methods for the treatment of multiple myeloma, smoldering multiple myeloma and secondary bone cancers. | 2009-11-19 |
| 20090286824 | Pyridine Classical Cannabinoid Compounds and Related Methods of Use - Disclosed are compounds of the formula I: | 2009-11-19 |
| 20090286825 | Indole derivatives as crth2 receptor antagonists - Compounds according to formula (I) wherein the radicals R | 2009-11-19 |
| 20090286826 | PHARMACEUTICAL COMPOSITIONS HAVING CARBOXYVINYL POLYMER AND POVIDONE POLYMER - The present invention is directed to pharmaceutical compositions, such as ophthalmic gels. The compositions typically include a carboxyvinyl polymer. A povidone polymer is also typically included to stabilize the carboxyvinyl polymer against agents or ingredients (e.g., therapeutic agent) that can otherwise cause instability to the carboxyvinyl polymer. | 2009-11-19 |
| 20090286827 | NOVEL BI-ARYL AMINES - The present invention relates to novel bi-aryl amines of formula (I) and to pharmaceutically acceptable prodrugs, salts, solvates, hydrates, and N-oxides thereof and to pharmaceutical compositions comprising them, methods of their use, and methods of their preparation. | 2009-11-19 |
| 20090286828 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES - The present invention relates to compounds of formula (I), or to salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof. | 2009-11-19 |
| 20090286829 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS - Disclosed herein are methods for treating a disorder associated with selective subtype modulation of alpha 2B and alpha 2C adrenergic receptors. Such methods can be performed, for example, by administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of at least one compound having the structure: | 2009-11-19 |
| 20090286830 | HETEROATOM-LINKED SUBSTITUTED PIPERIDINES AND DERIVATIVES THEREOF USEFUL AS HISTAMINE H3 ANTAGONISTS - Disclosed are novel compounds of the formula | 2009-11-19 |
| 20090286831 | VR1 Receptor Ligands and u-Opioid Receptor Ligands for the Treatment of Pain - A pharmaceutical composition comprising i) at least one composition that has affinity to the μ-opioid receptor, and at least one compound that has affinity to the VR1 receptor, or ii) at least one compound, in particular at least one compound corresponding to formula (I), (II), (III), (IV) or (V), that has affinity to the μ-opioid receptor and to the VR1 receptor, and also to the use of the pharmaceutical compositions i) and ii) for the production of a drug for the treatment of pain. | 2009-11-19 |
| 20090286832 | NARCOTIC EMULSION FORMULATIONS FOR TREATMENT OF SURGICAL PAIN - Methods and compositions of treating a subject for post-surgical pain are provided. In the subject methods, a subject is treated for post-surgical pain by administering to the subject an effective amount of a narcotic emulsion, e.g., fentanyl emulsion, formulation. In certain embodiments, the emulsion formulations include a narcotic active agent, oil, water and an surfactant. Also provided are methods of making the subject emulsion formulations as well as kits that include the emulsion formulations. | 2009-11-19 |
| 20090286833 | Substituted Cyclohexylmethyl Compounds - Novel cyclohexylmethyl compounds corresponding to formula I | 2009-11-19 |
| 20090286834 | Pyridine Analogues VI - The present invention relates to certain new pyridin analogues of Formula (I) to processes for preparing such compounds, to their utility as P2Y | 2009-11-19 |
| 20090286835 | NOVEL COMPOUNDS - The present invention provides compounds of formula (I) | 2009-11-19 |
| 20090286836 | Novel Compounds - The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R is C | 2009-11-19 |
| 20090286837 | Oxadiazole compounds as urokinase inhibitors - The present invention relates to novel compounds which inhibit urokinase-plasminogen activator (uPA), have a high bioavailability and can be administered orally, and to their use as therapeutic active substances for the treatment of disorders associated with urokinase and/or urokinase receptor, for example tumours and metastasis. The invention relates in particular to compounds containing oxadiazole groups. | 2009-11-19 |
| 20090286838 | TREATMENT FOR CANCER - The present invention provides methods for the treatment of tumors, comprising administration of an effective amount of at least one taxoid and an effective amount of at least one benzimidazol carbamate compound of formula (I). The invention also provides a method for the treatment of tumors insensitive to one or more anti-mitotic drugs, the method comprising administering an effective amount of at least one benzimidazole carbamate compound of formula (I). Also provide are compositions for carrying out methods of the invention. | 2009-11-19 |
| 20090286839 | PHYTONUTRIENT COMPOSITIONS FROM MUSHROOMS OR FILAMENTOUS FUNGI AND METHODS OF USE - This invention is directed to treating disease states or conditions associated with the treatment and prevention of neurodegeneration and neurodegenerative disease states, and treatment of radiation damage. The invention relates to novel phytonutrient compositions and compounds comprising L-ergothioneine and/or selenium. The invention also provides a method of administering these compositions and combinations to humans or animals in need thereof. | 2009-11-19 |
| 20090286840 | Thiophene-carboxamides useful as inhibitors of protein kinases - The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. | 2009-11-19 |
| 20090286841 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed. | 2009-11-19 |
| 20090286842 | NAPHTHYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS - Disclosed herein is a method of treating stress urinary incontinence comprising administering a compound to a mammal in need thereof, wherein said compound has the formula | 2009-11-19 |
| 20090286843 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION - The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 2009-11-19 |
| 20090286844 | Carvedilol phosphate - The invention encompasses novel amorphous and crystalline forms of carvedilol phosphate, carvedilol hydrogen phosphate, and carvedilol dihydrogen phosphate as well as methods of making the novel amorphous and crystalline forms. Also disclosed are pharmaceutical compositions comprising the novel amorphous and crystalline forms and uses thereof. | 2009-11-19 |
| 20090286845 | Carvedilol phosphate - The invention encompasses novel amorphous and crystalline forms of carvedilol phosphate, carvedilol hydrogen phosphate, and carvedilol dihydrogen phosphate as well as methods of making the novel amorphous and crystalline forms. Also disclosed are pharmaceutical compositions comprising the novel amorphous and crystalline forms and uses thereof. | 2009-11-19 |
| 20090286846 | Therapeutic use of N-(1H-Indolyl)-1H-indole-2-carboxamide derivatives - The invention relates to therapeutic use of compounds of general formula (I): | 2009-11-19 |
| 20090286847 | ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS OF USE THEREOF - Embodiments of the present invention provide for methods and compositions comprising an Oncorasin, such as 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1) and/or its analogs or derivatives. | 2009-11-19 |
| 20090286848 | NOVEL N-(2-AMINO-PHENYL)-ACRYLAMIDES - The present invention is directed to the compounds of formula | 2009-11-19 |
| 20090286849 | MODULATION OF INSULIN LIKE GROWTH FACTOR I RECEPTOR EXPRESSION - The present invention provides compositions and methods for modulating the expression of growth factor gene. In particular, this invention relates to compounds, particularly oligonucleotide compounds, which, in preferred embodiments, hybridize with nucleic acid molecules encoding the Insulin Like Growth Factor I receptor (IGF-I receptor or IGF-IR) and in particular human IGF-IR. Such compounds are exemplified herein to modulate proliferation which is relevant to the treatment of proliferative and inflammatory skin disorders and cancer. It will be understood, however, that the compounds can be used for any other condition in which the IGF-IR is involved including inflammatory condition. | 2009-11-19 |
| 20090286850 | Inhibition of EMT induction in tumor cells by anti-cancer agents - The present invention provides methods of identifying an agents that inhibit tumor cells from undergoing an epithelial to mesenchymal transition, impair tumor cell mobility, and thus inhibit tumorigenicity. The present invention also provides compositions comprising said agents, and methods for their preparation and use. The present invention also provides methods for inhibiting tumor cells in a patient from undergoing an epithelial to mesenchymal transition by administration of inhibitors of PAK2 kinase, that optionally also inhibit PAK1 kinase. Such methods may be employed in combination with other anti-cancer agents such as EGFR or IGF-1R kinase inhibitors. | 2009-11-19 |
| 20090286851 | Compositions and Methods for Delivering RNAI Using Lipoproteins - This invention relates to new compositions comprising at least one of a single or double stranded oligonucleotide, where said oligonucleotide has been conjugated to a lipophile and to which the conjugated oligonucleotide has been preassembled with lipoproteins. These compositions are effectively in delivering oligonucleotides to mammalian tissue where they effect gene silencing. | 2009-11-19 |
| 20090286852 | RNA containing modified nucleosides and methods of use thereof - This invention provides RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of RNA, oligoribonucleotide, and polyribonucleotide molecules. | 2009-11-19 |
| 20090286853 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION - Compounds comprising an oligonucleotide moiety covalently linked to a lipid moiety are disclosed. The oligonucleotide moiety comprises a sequence that is complementary to the RNA component of human telomerase. The compounds inhibit telomerase activity in cells with a high potency and have superior cellular uptake characteristics. | 2009-11-19 |
| 20090286854 | APTAMERS DIRECTED TO MUCI - Aptamers against the glycosylated form of MUC1 are described, along with their use in treatment and diagnosis of conditions associated with elevated production of MUC1. | 2009-11-19 |
| 20090286855 | INTERLEUKIN-18 MUTANTS, THEIR PRODUCTION AND USE - The invention provides mutants of IL-18 with lower affinity to IL-18BP than the wild type IL-18 molecule. | 2009-11-19 |
| 20090286856 | Method of Diagnosing Breast Cancer - Objective methods for detecting and diagnosing breast cancer (BRC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of a BRC-associated gene that discriminates between BRC cells and normal cells. In another embodiment, the diagnostic method involves determining the expression level of a BRC-associated gene that discriminates among BRC cells, between DCIS and IDC cells. The present invention further provides means for predicting and preventing breast cancer metastasis using BRC-associated genes having unique altered expression patterns in breast cancer cells with lymph-node metastasis. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of breast cancer, methods of treating breast cancer and method for vaccinating a subject against breast cancer. | 2009-11-19 |
| 20090286857 | GENE THERAPY FOR AMYOTROPHIC LATERAL SCLEROSIS AND OTHER SPINAL CORD DISORDERS - This disclosure provides methods and compositions for treating disorders or injuries that affect motor function and control in a subject. In one aspect, the invention a transgene product is delivered to a subject's spinal cord by administering a recombinant viral vector containing the transgene to the spinal cord. The viral vector delivers the transgene which expresses the encoded recombinant viral gene product. The viral gene product comprises HIF1-alpha. Also provided are compositions for delivery of a transgene product to a subject's spinal cord. | 2009-11-19 |
| 20090286858 | ASSAYS FOR MODULATORS OF ASPARAGINYL HYDROXYLASE - The present invention is directed to methods of identifying an agent which modulates hydroxylation of hypoxia inducible factor (HIF), comprising contacting a HIF asparagine hydroxylase and a test substance in the presence of a substrate of the hydroxylase under conditions in which asparagine in the substrate is hydroxylated in the absence of the test substance; and determining hydroxylation of the substrate. | 2009-11-19 |
| 20090286859 | POTENT LNA OLIGONUCLEOTIDES FOR THE INHIBITION OF HIF-1a EXPRESSION - The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5′-( | 2009-11-19 |
| 20090286860 | Method of using adenoviral vectors to induce an immune response - The invention provides a method of inducing an immune response against a human immunodeficiency virus (HIV) in a mammal. The method comprises administering to the mammal an adenoviral vector composition comprising one or more adenoviral vectors encoding two or more different HIV antigens, the production of which induces an immune response against HIV in the mammal. The invention also provides an adenoviral vector composition comprising four adenoviral vectors encoding an HIV clade A Env protein, an HIV clade B Env protein, an V clade C Env protein, and a fusion protein comprising an HIV clade B Gag protein and Pol protein, respectively. | 2009-11-19 |
| 20090286861 | PHENOTYPIC REVERSION OF PANCREATIC CARCINOMA CELLS - The present invention provides peptides (including analogs and derivatives thereof) corresponding to residues 96-110 and 35-47 of ras-p21, which peptides have attached thereto a membrane-penetrating leader sequence. The subject peptides, analogs and derivatives thereof are useful in treatment of cancers and have been shown to induce phenotypic reversion of pancreatic cancer cells to non-cancerous cells. Pharmaceutical compositions comprising one or more subject peptides are also provided by the present invention. The present invention further provides replication incompetent Adenovirus (AdV) vectors comprising a promoter sequence and a nucleotide sequence encoding a subject peptide. Methods of treating cancer by administering one or more subject peptides, pharmaceutical compositions, and/or AdV vectors are also provided. | 2009-11-19 |
| 20090286862 | Therapeutic agent for psychoneurotic disease - The present invention relates to a preventive and/or therapeutic agent for psychoneurotic diseases, comprising an EP | 2009-11-19 |
| 20090286863 | SULFAMATOBENZOTHIOPHENE DERIVATIVES - The invention relates to novel compound of the general formula (I), in which R has the meanings indicated in Claim | 2009-11-19 |
| 20090286864 | Coating agent for drug releasing stent, preparation method thereof and drug releasing stent coated therewith - Disclosed are a coating agent for drug releasing stents, a method for preparing the same and a drug releasing stent coated therewith. The coating agent for drug releasing stents comprises nanoparticles with a biologically active material entrapped therein, wherein the particles are formed of a polyethyleneimine (PEI)-deoxycholic acid (DOCA) polymer (PDo) in which 1˜8 moles of DOCA are grafted per mole of PEI. | 2009-11-19 |
| 20090286865 | POTENTIATOR OF ANTITUMORAL AGENTS IN THE TREATMENT OF CANCER - The present invention relates to a potentiator composition for enhancing therapeutical effect of an antitumoral agent, said composition comprising a terpene or derivative thereof in association with a pharmaceutically acceptable carrier. | 2009-11-19 |
| 20090286866 | Double compartment skincare products comprising avermectin/milbemycin compounds - Double compartment skincare products confine a first compartment containing an anhydrous composition including an active ingredient, and a second compartment, wherein the active ingredient is selected from among compounds of the avermectin family and compounds of the milbemycin family, and are useful as medicaments for the treatment and/or prevention of dermatological conditions/afflictions. | 2009-11-19 |
| 20090286867 | COMPOSITIONS AND METHODS OF ADMINISTERING DOXEPIN TO MUCOSAL TISSUE - Compositions and methods for pain relief involve delivery of doxepin to mucosal tissue. Vehicles for administering doxepin may be formulated for sustained release and/or site-specific application to maximize beneficial pain relief locally while minimizing significant adverse side effects. | 2009-11-19 |
| 20090286868 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS - A compound corresponding to general formula (I): | 2009-11-19 |
| 20090286869 | Flavanols and B-Type Procyanidins and Inflammation - The invention relates to compositions, and methods of use thereof, containing certain polyphenols such as flavanols, procyanidins and derivatives thereof for treating inflammation and/or inflammation-related or associated disease or condition, and/or for the relief of pain, in a subject sensitive to a selective cyclooxygenase-2 (COX-2) inhibitor and/or a subject sensitive to a COX-nonselective nonsteroidal anti-inflammatory drug (NSAID). | 2009-11-19 |
| 20090286870 | Cancer Treatment Using FTS and 2-Deoxyglucose - Methods of treating cancer by administering effective amounts of a Ras antagonist comprising FTS, or analogs thereof, or a pharmaceutically acceptable salt, and 2-deoxyglucose (2DG) to a patient are disclosed. Pharmaceutical compositions useful in treating cancer containing a Ras antagonist comprising FTS, or analogs thereof, or a pharmaceutically acceptable salt, and 2DG are also disclosed. | 2009-11-19 |
| 20090286871 | Use of a plant oil product as an agent for increasing the synthesis of skin lipids - The present invention relates to the use of a plant oil product as an agent for increasing the synthesis of skin lipids, especially the lipids of the epidermal skin barrier, in or for the preparation of a cosmetic, pharmaceutical or dermatological composition. The invention also relates to a method for cosmetic treatment with a cosmetic, pharmaceutical or dermatological composition for increasing the synthesis of skin lipids, especially the lipids of the epidermal skin barrier, and to the use of the plant product as a food additive. | 2009-11-19 |
| 20090286872 | Oral Composition Comprising Dha and Genistein for Enchancing Skin Properties - Composition for oral consumption in the form of a substantially 5 homogeneous aqueous emulsion, suspension or dispersion comprising genistein and docosahexaenoic acid (DHA) and less than 1% by weight of soy protein, wherein the weight ratio of genistein to DHA is in the range of from 1:100 to 1:1, the composition comprises genistein in an amount of from 0.0001% to 0.1% by 10 weight and the genistein and DHA exhibit an anti-ageing effect on skin. | 2009-11-19 |
| 20090286873 | AI-2 compounds and analogs based on Salmonella typhimurium LsrB structure - This invention relates to crystals comprising apo-LsrB and holo-LsrB. The structure of holo-LsrB identifies a tetrahydroxytetrahydrofuran derived from 4,5-dihydroxy-2,3-pentanedione (DPD) as the active autoinducer-2 (AI-2) molecule in | 2009-11-19 |
| 20090286874 | Anti-aging composition containing phloretin - An anti-aging composition containing: (a) at least one first active ingredient chosen from phloretin and its derivatives; (b) at least one second active ingredient chosen from cinnamic acid, resveratrol, retinol, ascorbic acid, tocopherol, and their derivatives; and (c) at least one non-aqueous organic solvent, with the proviso that if the composition contains ascorbic acid, water is present as a co-solvent. | 2009-11-19 |
| 20090286875 | ISOCYSTENE DERIVATIVES FOR THE TREATMENT OF PAIN - The present invention relates to compounds of formula (I): wherein R | 2009-11-19 |
| 20090286876 | NEUROPROTECTIVE BENZOATE AND BENZAMIDE COMPOUNDS - The invention provides a therapeutic method for treating at least one symptom of a neurological disorder or disease such as Alzheimer's disease in a mammal, such as a human, wherein the toxicity of a pathogen of β amyloid peptide and/or glutamate in mammalian cells is implicated and inhibition of the subsequently-induced pathological pathways is desired comprising administering to a mammal in need of such therapy, an effective amount of an N-arylamide or an (N-aminoalkyl)benzamide, including pharmaceutically acceptable salts thereof. | 2009-11-19 |
| 20090286877 | PESTICIDAL/OVICIDAL COMPOSITION AND PESTICIDAL/OVICIDAL METHOD - A pesticidal/ovicidal composition comprising (a) 50-99.9 parts by mass of a triglyceride containing not less than 50% of oleic acid as a fatty acid component; (b) 0.1-20 parts by mass of a nonionic surface active agent; and (c) 0-30 parts by mass of a glycerin derivative. The composition according to the invention has not only a pesticidal activity but also an ovicidal activity on crop pests, and provides a safe and high pesticidal/ovicidal effect. | 2009-11-19 |
| 20090286878 | POLYOL DERIVED ANTI-MICROBIAL AGENTS AND COMPOSITIONS - Anti-microbial compositions are provided which comprise as an antimicrobial agent at least one compound derived from a select polyol containing at least 3 hydroxy groups wherein one or more, and often two or more, of the hydroxyls are derivitized to form certain ether, ester, carbonate or carbamate groups which groups may bear additional functionality. Novel antimicrobial compounds of this class are also provided. The compositions are effective against a variety of pathogens including fungi, Gram positive bacteria and Gram negative bacteria and are expected to have low human toxicity. Applications for the polyglycerol anti-microbial agents and compositions include those involving human and plant contact, such as cosmetics, hair care products, textiles and plant protections, as well as in applications with much less human contact, such as plastics, coatings, wood, paper and other materials of construction. | 2009-11-19 |
| 20090286879 | Preventive or Therapeutic Drug for Alzheimer-Type Dementia - It is intended to provide a highly safe preventive or therapeutic drug for Alzheimer-type dementia which can replace the conventional therapies currently used for Alzheimer-type dementia or which can be used together with the conventional therapy to realize high therapeutic effects, characterized in that a ω-3 polyunsaturated fatty acid and thyroid hormone are used in combination. | 2009-11-19 |
| 20090286880 | NOVEL PROCESS - The present invention relates to a novel process for the preparation of γ-amino acids, such as (±)-3-(aminomethyl)-5-methyl-hexanoic acid 1, which is a key intermediate in the preparation of the potent anticonvulsant pregabalin, (S)-(+)-3-(aminomethyl)-5-methyl-hexanoic acid 2. | 2009-11-19 |
| 20090286881 | SELECTED BETAINES AND THEIR USES - A physiologically acceptable, sterile and pyrogen-free solution of betaine dissolved in a physiologically acceptable solvent, having a pH adjusted to from 5.0 to 8.0 with a betaine concentration of from 5 to 500 mg/ml. | 2009-11-19 |
| 20090286882 | Cyclopropylacetic Acid Derivatives and Use Thereof - The present application relates to novel cyclopropylacetic acid derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prevention of cardiovascular disorders. | 2009-11-19 |
| 20090286883 | TREATMENT OF HEART FAILURE AND ASSOCIATED CONDITIONS BY ADMINISTRATION OF MONOAMINE OXIDASE INHIBITORS - Administration of monoamine oxidase inhibitors is useful in the prevention and treatment of heart failure and incipient heart failure. | 2009-11-19 |
| 20090286884 | Hops Beta-Acid Anti-Diabetic Composition - The invention relates to compositions and processes for reducing the level of blood glucose or ameliorating diabetic symptoms in a subject by treatment with the composition which includes one or more safe and suitable hops acids or hops acid derivatives. More specifically, the process comprises using an ingredient or applying to a food or a nonfood product a composition-comprising beta hops acids in order to reduce blood glucose levels in Type 2 diabetics or its related diseases. | 2009-11-19 |
| 20090286885 | Ethylene-tetrafluoroethylene phosphate composition - A composition comprising a compound of formula (I) or (II): | 2009-11-19 |
| 20090286886 | RESORBABLE POLYMER COMPOSITIONS FOR USE IN MEDICINE, DENTISTRY, AND SURGERY - We describe the medical, dental, and surgical uses of modified poly(alkylene) materials which are fully resorbable after implantation into the body, and compositions formulated with such modified poly(alkylene) materials. | 2009-11-19 |
| 20090286887 | STABILISATION OF COLORANTS IN COSMETIC AND DERMATOLOGICAL PREPARATIONS - Methods of stabilizing color in a composition, which methods comprise: (a) providing an amino-substituted hydroxybenzophenone compound corresponding to the general formula (I): | 2009-11-19 |
| 20090286888 | METHOD OF PREPARING AN AGGREGATE METAL OXIDE PARTICLE DISPERSION HAVING A DESIRED AGGREGATE PARTICLE DIAMETER - The invention provides an aqueous dispersion of aggregate silica particles comprising aggregate silica particles having an aggregate structure comprised of fused primary particles, wherein the aggregate silica particles have a primary particle diameter and an aggregate particle diameter, and the average of the primary particle diameters (d | 2009-11-19 |
| 20090286889 | INTEGRATED COAL TO LIQUIDS PROCESS AND SYSTEM - An integrated coal-to-liquids process is provided to minimize carbon dioxide emissions and efficiently make use of carbon resources, by recovering carbon dioxide emissions from Coal-to-Liquids (CTL) facilities, using the recovered carbon dioxide in at least one carbonylation reaction step for converting ammonia to urea and then converting urea into dimethyl carbonate. | 2009-11-19 |
| 20090286890 | METHOD FOR RECOVERING A NATURAL GAS CONTAMINATED WITH HIGH LEVELS OF CO2 - The present invention provides a method for recovering a natural gas contaminated with high levels of carbon dioxide. A gas containing methane and carbon dioxide is extracted from a reservoir containing natural gas, where carbon dioxide comprises at least 50 vol. % of the extracted gas. The extracted gas is oxidized with an oxygen containing gas in the presence of a partial oxidation catalyst at a temperature of less than 600° C. to produce an oxidation product gas containing hydrogen, carbon monoxide, and carbon dioxide. The oxidation product gas is then utilized to produce a liquid hydrocarbon or a liquid hydrocarbon oxygenate. | 2009-11-19 |
| 20090286891 | ION-PAIR CHARGE-TRANSFER COMPLEX POLYMER AND PHOTORESPONSIVE-ELECTRORESPONSIVE MATERIAL COMPRISING THE SAME - Provided is a novel ion-pair charge-transfer complex polymer suitable for use as a photo-functional material which shows extremely fast photoresponses in the wide wavelength range from visible to near infrared regions, and thermally stable. | 2009-11-19 |
| 20090286892 | PROCESS FOR THE PRODUCTION OF RECYCLED POLYCARBONATE AS RAW MATERIAL FOR FLAME-RETARDANT RESIN COMPOSITIONS AND POLYCARBONATE-BASE FLAME-RETARDANT RESIN COMPOSITIONS - A method for manufacturing a recycled polycarbonate raw material for a flame retardant resin composition from discarded and/or recovered optical discs using a polycarbonate resin as a substrate material, and includes (a) a step to identify if 2,2-bis(4-hydroxyphenyl)propane as a divalent phenol of the polycarbonate resin raw material is polymerized as the sole raw material in the polycarbonate resin as the substrate material of the discarded and/or recovered optical discs and (b) a step to remove impurities by a chemical treatment by separating only the discarded and/or recovered optical discs, wherein the polycarbonate resin is identified as polymerized by using 2,2-bis(4-hydroxyphenyl)propane as the sole raw material. Accordingly, used optical discs using a PC resin as a substrate material and discarded optical discs as substandard articles in a manufacturing step can be reused as a raw material for a flame retardant polycarbonate resin composition by treating with a method at low cost and a low environmental load. | 2009-11-19 |
| 20090286893 | METHOD FOR PRODUCING MULTI-LAYERED THERMOPLASTIC ELASTOMER MATERIAL - The present invention relates to a method of producing multi-layered thermoplastic elastomer (TPE) composition. The TPE is used to be a polymer matrix of the material. The method comprising: (A) choosing and adding a cross-linking agent to retain the thermoplastic-property of the TPE, and (B) combining different layers by using a thermal-pressing process without glue for bonding and forming a multi-layered TPE material. | 2009-11-19 |
| 20090286894 | POROUS POLYMER BLEND STRUCTURES - A porous polymer blend, and a method of producing a porous polymer blend from at least two immiscible polymers. The at least two immiscible polymer being blended together and exhibiting the absence of complete phase separation. The method of producing a porous polymer blend comprising: forming a liquid composition comprising at least two immiscible polymers dissolved in a common solvent; subjecting the liquid composition to a reduction in temperature to cause at least two immiscible polymers to phase separate into a common polymer rich phase and a common polymer poor phase; solidifying the at least two immiscible polymers in the common polymer rich phase so as to avoid complete phase separation of the at least two immiscible polymers; and removing the common polymer pore phase to provide a blend of the at least two immiscible polymers having a porous morphology. | 2009-11-19 |
